TLR7

Gang Liu1, Tatt Jhong Haw2, Malcolm R Starkey3

  • 1Centre for Inflammation, Centenary Institute, and Faculty of Science, University of Technology Sydney, Camperdown, New South Wales, Australia.

Nature communications
|November 14, 2023
PubMed
概括

收费类受体7 (TLR7) 驱动肺气和慢性阻塞性肺病 (COPD) 严重程度,特别是通过巨细胞活性. 针对TLR7可能为COPD患者提供新的治疗策略.

相关概念视频